LEADER 04190nam 2200613Ia 450 001 9910820007503321 005 20240516122658.0 010 $a1-60805-132-3 035 $a(CKB)2670000000067026 035 $a(EBL)864213 035 $a(OCoLC)819594352 035 $a(SSID)ssj0000494865 035 $a(PQKBManifestationID)11326006 035 $a(PQKBTitleCode)TC0000494865 035 $a(PQKBWorkID)10453020 035 $a(PQKB)11295234 035 $a(MiAaPQ)EBC864213 035 $a(Au-PeEL)EBL864213 035 $a(CaPaEBR)ebr10447992 035 $a(EXLCZ)992670000000067026 100 $a19990506d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAnastin and malignant gliomas$b[electronic resource] /$feditor, Thomas C. Chen ; co-editor, Marc Chamberlain 205 $a1st ed. 210 $a[S.l.] $cBentham e Books$d[2011] 215 $a1 online resource (219 p.) 225 0 $aControversies in neuro-oncology 300 $aDescription based upon print version of record. 311 $a1-60805-519-1 320 $aIncludes bibliographical references and indexes. 327 $a01 Cover Page.pdf; 02 Title Page; 03 eBooks End User License Agreement-Website; 04 table of contents; 05 Foreword; 06 PREFACE-Avastin; 07 Contributors; 08 Part 1 BASIC SCIENCE AND RATIONALE; 09 Ch-1; 10 Part 2; 11 Ch-2 Desjardins-Avastin-recurrent-chen; 12 Ch-3 kreisl-Avastin_and_Mailgnant_Gliomas_-_Is_there_a_role[1]-chen; 13 Ch-4 GutinRT-_bev_review_FI_PG_9-22[1]-chen; 14 Ch-5 norden_controversies_6-19-09[1]-chen; 15 Part 3; 16 Ch-6 Reardon_chapter_8[1].29; 17 Ch-7 Mehta-radiationControversies_in_Neuro-Avastin-final[1]-chen 327 $a18 Ch-8 Gilbert-Bevacizumab_and_Malignant_Glioma_final_version_9-14-09[1]-Gilbert-chen19 Part 4; 20 Ch-9 Schiff-Avastin toxicityFinal-Bevacizumab_Toxicity_in_Glioblastoma_with_DS_edits_090109-for_review_11[1]-chen corrected; 21 Ch-10 Rogers Chapter_-_Avastin_and_AC_-_Chamberlain_11-2-09__3_[2]-Chen; 22 Part 5; 23 Ch-11 Raizer- AvastinFinal__2_[1]-chen; 24 Part 6; 25 Ch-12 POPE_GBM_Avastin_Imaging[1]-chen; 26 Ch-13 Butowski-radiographic responses 2-chen; 27 Ch-14 Imaging Responses of Bevacizuma; 28 Ch-15 HENSON091509cleanref[1]-chen; 29 Part 7; 30 Ch-16 Aghi-_Avastin_v2[1]-Chen 327 $a31 Ch-17 Vogelbaum-Surgical Implications-Avastin_Final[1]-chen32 Part 8; 33 Ch-18 chamberlain-BevNovelApplications_8_6_09[1]-chen; 34 Ch-19 Levin-Radiation_necrosis-082509-Final[1]-chen; 35 Ch-20 chamberlain-salvage-chen; 36 Part 9; 37 Ch-21 StuppBev_rec_glioma__final[1]-chen; 38 Ch-22 van den Bent-Avastin in Europe-chen; 39 Ch-23 Avastin_Weller_2009-6-30[1]-chen; 40 Ch-24 Wick European pers-chen; 41 Part 10; 42 Ch-25 Sunitinib_ebook_chapter___B_Neyns[1]-chen; 43 Ch-26 nabors-cilengitide-chen; 44 Ch-27 SorafenibChapter_FINAL[2]-chen; 45 Ch-28 Wen-VEGF-trap_8-14-09_FINAL[1]-chen 327 $a46 Ch-29 Batchelor-Gerstner-Dietrich-Cediranib-09-12-09[1]-chen47 Part 11 Conclusion; 48 Ch-30 Gu Development_of_Bevacizumab[1][1]-chen; 49 Author Index -Avastin; 50 Index-final-chen 330 $aNeuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconclusive because of the limited number of patients involved. As a result, many controversies exist in neuro-oncology drug development for which a forum does not exist. This ebook presents a detailed account on the use of avastin in treating cancer patients. A discussion on clinical experiences and the controversial debate among researchers of ava 410 0$aControversies in Neuro-Oncology, 1 606 $aGliomas 606 $aBevacizumab 615 0$aGliomas. 615 0$aBevacizumab. 676 $a616.8 701 $aChen$b Thomas C$01688857 701 $aChamberlain$b Marc C$01688858 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910820007503321 996 $aAnastin and malignant gliomas$94063425 997 $aUNINA